Rafael's Lead Drug Misses Phase 3 Primary Endpoint, Subgroup Offers Hope
RFL is trading near its 52-week low of $1.12 (11% above the low).
Summary
Rafael Holdings' lead asset Trappsol Cyclo failed its Phase 3 primary endpoint, a major setback for the company's only late-stage program. However, a prespecified subgroup of patients on miglustat and/or leucine showed statistically significant efficacy, which the company believes supports an NDA submission in Q4 2026. Safety data revealed a higher rate of serious treatment-emergent adverse events (35.9% vs 16.7%) and one case of severe bilateral deafness, which could draw FDA scrutiny. The mixed results leave approval uncertain, but the subgroup data and planned NDA keep the program alive. This follows the July 8-K confirming completion of a pre-NDA meeting, indicating the company is moving forward despite the miss.
Updates
· SEC 8-K — The 8-K includes the full press release with detailed efficacy and safety data, including a 64% slowing of disease progression on the primary endpoint (p=0.19) and a 71% slowing in the prespecified subgroup (p=0.046).
At the time of this announcement, RFL was trading at $1.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $105.6M. The 52-week trading range was $1.12 to $3.96. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.